Janux Therapeutics (NASDAQ:JANX) Stock Price Breaks Above 50-Day Moving Average – Here’s What Happened

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $17.49 and traded as high as $17.81. Janux Therapeutics shares last traded at $17.63, with a volume of 852,234 shares traded.

Janux Therapeutics News Summary

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 from $36 and reiterated its outperform rating, implying substantial upside from the cited $17.63 share price. Wedbush raises Janux price target
• Positive Sentiment: Truist raised its target to $27 from $26 and maintained a buy rating, signaling continued confidence in JANX. Truist analyst recommendations
• Positive Sentiment: Janux reported a third-quarter loss of $0.34 per share, narrower than analysts’ expected loss of $0.45–$0.47. Revenue of $9.29 million also exceeded the $8.03 million estimate. The results beat expectations, although the company remained loss-making. Janux third-quarter 2026 results
• Neutral Sentiment: Janux said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007, marking progress in its clinical pipeline; the update does not establish how the treatment will perform. Janux business highlights
• Negative Sentiment: Barclays raised its target only to $15 from $14 but kept an underweight rating, placing its target below the cited share price and underscoring a bearish view that contrasts with other analysts. Barclays analyst recommendations

Wall Street Analyst Weigh In

JANX has been the subject of a number of recent research reports. Wedbush upped their price objective on Janux Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday. Guggenheim lowered their price objective on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Barclays raised their target price on shares of Janux Therapeutics from $14.00 to $15.00 and gave the stock an “underweight” rating in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Friday, October 16th. Finally, HC Wainwright restated a “buy” rating on shares of Janux Therapeutics in a report on Monday, October 19th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Janux Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $36.92.

Janux Therapeutics Stock Performance

The business has a 50 day moving average of $17.49 and a 200-day moving average of $15.42. The company has a market capitalization of $1.08 billion, a P/E ratio of -11.09 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13. The firm had revenue of $9.29 million for the quarter, compared to the consensus estimate of $8.03 million. As a group, equities analysts forecast that Janux Therapeutics, Inc. will post -1.70 EPS for the current fiscal year.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its stake in Janux Therapeutics by 67.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock valued at $28,000 after purchasing an additional 661 shares in the last quarter. Versant Capital Management Inc lifted its holdings in Janux Therapeutics by 42.8% during the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after buying an additional 784 shares during the last quarter. Fulcrum Asset Management LLP lifted its holdings in Janux Therapeutics by 3,391.2% in the third quarter. Fulcrum Asset Management LLP now owns 2,374 shares of the company’s stock valued at $40,000 after acquiring an additional 2,306 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Janux Therapeutics in the third quarter worth approximately $54,000. Finally, Quantbot Technologies LP increased its holdings in Janux Therapeutics by 2,290.0% in the second quarter. Quantbot Technologies LP now owns 5,497 shares of the company’s stock valued at $84,000 after buying an additional 5,267 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.